164 related articles for article (PubMed ID: 20832836)
1. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.
Gromowski GD; Roehrig JT; Diamond MS; Lee JC; Pitcher TJ; Barrett AD
Virology; 2010 Nov; 407(2):237-46. PubMed ID: 20832836
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
Gromowski GD; Barrett AD
Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
[TBL] [Abstract][Full Text] [Related]
3. A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3.
Sarathy VV; Pitcher TJ; Gromowski GD; Roehrig JT; Barrett ADT
J Gen Virol; 2017 Jun; 98(6):1299-1304. PubMed ID: 28631593
[TBL] [Abstract][Full Text] [Related]
4. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.
Gromowski GD; Barrett ND; Barrett AD
J Virol; 2008 Sep; 82(17):8828-37. PubMed ID: 18562544
[TBL] [Abstract][Full Text] [Related]
5. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III.
Matsui K; Gromowski GD; Li L; Schuh AJ; Lee JC; Barrett AD
Virology; 2009 Feb; 384(1):16-20. PubMed ID: 19101005
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.
Falconar AK
Clin Vaccine Immunol; 2008 Mar; 15(3):549-61. PubMed ID: 18160621
[TBL] [Abstract][Full Text] [Related]
7. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.
Goncalvez AP; Purcell RH; Lai CJ
J Virol; 2004 Dec; 78(23):12919-28. PubMed ID: 15542644
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III.
Matsui K; Gromowski GD; Li L; Barrett AD
J Gen Virol; 2010 Sep; 91(Pt 9):2249-53. PubMed ID: 20444995
[TBL] [Abstract][Full Text] [Related]
9. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.
Li L; Barrett AD; Beasley DW
Virology; 2005 Apr; 335(1):99-105. PubMed ID: 15823609
[TBL] [Abstract][Full Text] [Related]
11. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
Hiramatsu K; Tadano M; Men R; Lai CJ
Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
Roehrig JT; Bolin RA; Kelly RG
Virology; 1998 Jul; 246(2):317-28. PubMed ID: 9657950
[TBL] [Abstract][Full Text] [Related]
15. Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.
Dowd KA; DeMaso CR; Pierson TC
mBio; 2015 Nov; 6(6):e01559-15. PubMed ID: 26530385
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.
Frei JC; Kielian M; Lai JR
Virology; 2015 Nov; 485():371-82. PubMed ID: 26339794
[TBL] [Abstract][Full Text] [Related]
17. Dengue virus type 2 envelope protein displayed as recombinant phage attachment protein reveals potential cell binding sites.
Abd-Jamil J; Cheah CY; AbuBakar S
Protein Eng Des Sel; 2008 Oct; 21(10):605-11. PubMed ID: 18669522
[TBL] [Abstract][Full Text] [Related]
18. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
19. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
[TBL] [Abstract][Full Text] [Related]
20. Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1.
Zou G; Kukkaro P; Lok SM; Ng JK; Tan GK; Hanson BJ; Alonso S; MacAry PA; Shi PY
Antiviral Res; 2012 Sep; 95(3):216-23. PubMed ID: 22771779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
